Evolving SMA Treatment Landscape
Health care professionals working through this eLearning module will gain a detailed understanding of the most important recent developments in the treatment of patients with spinal muscular atrophy (SMA). The interactive module discusses antisense oligonucleotide therapy for different types of patients, and also addresses other emerging treatments for SMA. After completing the module, learners will be able to explain the mechanisms of action of current and emerging therapies, understand the main findings of the key clinical trials, and describe how the approved treatment is changing outcomes for patients with SMA.
This activity has been designed to meet the educational needs of neurologists, pediatricians, pulmonologists, physical therapists, and other HCPs, such as orthopedic surgeons, who are involved in the diagnosis, treatment, or management of patients with SMA.
Upon completion of this activity, participants will be able to:
- Explain the MoA of novel and emerging treatments
- Summarize clinical trials of novel and emerging treatments
- Apply the above knowledge to optimally select eligible patients and manage in daily clinical practice
Russell Butterfield, MD, PhD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
Russell Butterfield, MD, PhD
|Has no relationships with commercial interests|
Non-faculty: Marijke Verhaaf; Cordelia Nagle; Elena Knoche, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Biogen.
Jointly provided by the Elsevier Office of Continuing Medical Education, Dannemiller, and Ology Medical Education.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Ology Medical Education. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Credits (Nursing)
In support of improving patient care, this activity has been planned and implemented by Dannemiller and Elsevier Office of Continuing Medical Education. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this educational activity for 0.5 contact hours.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Dannemiller, Ology Medical Education, and Biogen do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Nursing Contact Hours
- 0.50 Non-physician